Niagen Bioscience, Inc. Common Stock
NAGEStock
$3.40−68.68%52W
Market Cap$271.95M
P/E15.65x
Div yield—
Beta2.12
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-56.64%
Price vs S&P 500 (4W)0.57%
VGM Score47.14
Market Capitalization$271.95M
P/E Ratio (Annual)15.65x
Earnings Surprise History
Q1 260.07est. 0.07
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.27
4.27
4.27
4.27
Industry Peers — Pharmaceutical Preparations(21)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
NAGENiagen Bioscience, Inc. Common Stock | C | B | D | $3.40 |
| DFTXDefinium Therapeutics, Inc. Common Shares | — | — | A | $44.10 |
| RGCRegencell Bioscience Holdings Limited Ordinary Shares | — | — | F | $4.78 |
| TRLVTrulieve Cannabis Corp. | B | C | A | $8.41 |
| CRONCronos Group Inc. Common Share | C | B | B | $2.75 |
| GLASGlass House Brands Inc. | C | C | B | $10.34 |
| TLRYTilray Brands, Inc. Common Stock | B | B | D | $4.35 |
| USNAUSANA Health Sciences Inc | B | D | C | $22.65 |
| CGCCanopy Growth Corporation Common Shares | B | C | C | $0.93 |
| SNDLSundial Growers Inc. Common Shares | A | C | C | $1.29 |
| MDWDMediWound Ltd. | D | F | D | $14.61 |
About
Niagen Bioscience Inc develops NAD+-boosting therapeutics focused on extending healthspan and addressing age-related decline. The company's clinically proven flagship ingredient effectively raises NAD+ levels and serves as the foundation for its product portfolio. Leveraging precision science approaches, Niagen targets the growing healthy-aging market with evidence-based solutions.